Siden 2016 har vi utvidet både sortimentet og antall butikker. Nå selger vi julepysjer, onesies og masse morsomt tilbehør i tillegg til vårt store utvalg av julegensere. Vi sender til hele Europa fra flere lagerhus, og det er ingenting som gleder oss mer enn å se våre fornøyde kunder vise frem julegenserne våre i sosiale medier, samt alle de tusenvis av gode tilbakemeldingene vi har fått på e-post og telefon.

Cavai AS was founded in December 2017 with the goal of revolutionizing online advertising. User experiences have largely been neglected on the web, and Cavai saw early on that chatbot technology, which has initially been used in customer service, could be a wonderfully good advertising product. Usually, chatbot technology is used as customer service on its own website, while Cavai's platform is built to be able to use chatbot technology on millions of websites for contextual advertising. The team today consists of 15 people, and the product has been launched in Norway, Finland, Sweden and the UK with 50 paying customers. Customers are very pleased and report that Cavai's technology is having a very good effect on completed advertising campaigns. Cavai will have its first month of positive operating results in October and looks to have sales of around 3 million in 2019. Next year will be a big growth year, where we have budgeted with a turnover of NOK 41 million. This growth has also been discussed by Finansavisen, where as part of Finansavisen's web-TV series "Vext", Cavai filmed his meeting with advertising legend Sir Marting Sorell in London. For more information, see https://finansavisen.no/vext/tech/2019/10/23/7465643/chatbot-company-cavai-2020-blir-the-store-growst>  To finance further growth, we are now running a seed funding round of NOK 9.5 - 15 million. The company is priced at NOK 60 million pre-money. For more information see the investor summary, investor presentation and subscription form attached.

BabySensor is developing a new unique monitor that measures the most important factors for a baby's health and well-being. It is the only product of its type monitoring heartbeat, temperature, lying position and baby’s cry. It is based on ground-breaking research and provides valuable information to parents through a mobile app. Safety is a high priority for families, and the trend shows a growing market within baby monitoring systems. We have a reliable, competent and experienced team who will succeed in turning the prototype into an attractive product.

New technologies, new regulations, and new players are forever changing the way consumers AND businesses think about payments. At EedenBull we want to drive change and leverage the vast untapped opportunities that emerge from it. We are all about payments and to us, customer centricity is key. Our mission is to challenge the existing, aggressively look for weaknesses, seek to improve, and change the way people and businesses pay and get paid – anytime, anywhere.

Deploi.no tilbyr virtuelle servere, enkelt og greit. Vi legger vi stor vekt på å øke servernes ytelse, samtidig som vi presser prisene nedover. Vi opplever etablerte aktører i bransjen som tunge og dyre, og ønsker å gjøre noe med dette.Vi kan skilte med en rekke forhåndsinstallerte operativsystemer og applikasjoner, og våre produkter skal være enkle å administrere.

code11 is a boutique design, development and consultancy company based in Oslo, Bucharest and Berlin. We work closely together with our customers and partners to create great customer experiences by applying new methodologies and utilizing cutting edge technology. code11 has been built brick by brick with Agile core values and cutting edge development technologies. We power start-ups and work in innovation programs as their tech partner, because we believe that there is always a better way to do it, whether it’s methodology, technology or digital transformation.

Ava was acquired by Motorola Solutions in 2022 and is now part of its portfolio. Ava is a global technology company with offices in the UK, Norway, and the USA. We exist because we believe that we can create a better, smarter way to deliver security. We help organizations see, understand, and act on their surroundings to protect their people, business, and reputation in real time.

The future of the internet is 3D, and people will increasingly create and express themselves in 3D. Sloyd is using automation to make the creation of 3D faster and more accessible and to make 3D rendering more efficient. We are building a simple-to-use WebApp to quickly generate 3D assets and a software development kit for performance-efficient runtime creation in video games and virtual worlds. Sloyd combines procedural generation techniques, machine learning, and a commitment to real-time optimization to provide the best 3D automation tools. Sloyd is a remote-first company and employees can work from home, a shared-space hub, or from the main office in Oslo. We don’t care where you come from, we only care about your passion and creativity.

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

OncoImmunity is a bioinformatics company providing unique machine-learning software to identify tumor-specific mutations that can be targeted by a patient’s own immune system (known as neoantigens). The OncoImmunity solution is important because recent breakthroughs in the field of Immuno-Oncology (I-O) such as the development of checkpoint inhibitors and personalized cancer vaccines, clearly demonstrate that a patient’s immune system can be harnessed to successfully treat cancer. The cost of identifying tumor-specific mutations in a patient’s cancer using next-generation sequencing (NGS) is now trivial and this technology will be key to enabling truly personalized immunotherapies to be developed in a technically and economically feasible manner. However, the remaining challenge that currently limits the field, and which is addressed by the OncoImmunity solution, is predicting which tumor-specific mutations can stimulate a patient’s immune system i.e. are immunogenic. Using NGS data as input, the OncoImmunity software enables accurate patient selection for cancer immunotherapy and can identify optimal targets for personalized cancer vaccines & cell therapies in a clinically actionable time frame. Beginning from this first product offering, OncoImmunity has the vision to become the world’s leading provider of software to guide cancer immunotherapy to improve survival rates for cancer patients. To achieve this OncoImmunity has assembled a growing team of world-class bioinformaticians, data scientists, and software engineers; developing its cutting-edge machine-learning technology that will help fulfill the promise of immunotherapy in the fight against cancer. OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size to access OncoImmunity’s cutting-edge prediction software. The company is headquartered in an ideal scientific and entrepreneurial ecosystem to develop its technology at the Oslo Cancer Cluster Incubator; adjacent to the Institute for Cancer Research and the Norwegian Radium Hospital. OncoImmunity is a privately held company, founded in 2014 by experienced bioinformatics scientists (Dr. Trevor Clancy and Professor Eivind Hovig), and an experienced immunologist with a business development background (Dr. Richard Stratford). The company is backed by private financing from the Norwegian Radium Hospital Research Foundation, the Norwegian Cancer Society, STARTUPLAB, and Grotmol Solutions, in addition to a number of private software investors. The company is also supported by grants awarded from the Norwegian Research Council, Innovation Norway, and the EU. The company has already established both national and international collaborations and pilot projects to develop further proof-of-concept data and validate its software.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Innovation Dock is a living, energetic innovation hub for entrepreneurs, innovators, and growth companies in Stavanger, Norway. Four buildings of prime office space, co-working, and conference facilities with a front-row view of the fjords and mountains, located in the most energetic part of Stavanger city center; the growing Stavanger east.

Vi tør å tenke nytt i en bransje som er preget av umoderne arbeidsformer, og kombinerer tung juridisk kompetanse med markedsledende teknologi. LIGL ble startet for å utfordre den konservative advokatbransjen, og bygger på tre grunnleggende prinsipper, kompetanse, kultur og teknologi – vårt DNA. Gjennom innovativ bruk av teknologi, en moderne forretningsmodell og et unikt arbeidsmiljø, vil vi skape et reelt, effektivt og eksklusivt alternativ til de største advokatfirmaene i Norge. Vi vet at dette vil og må ta tid, men vi vet også at det er denne veien bransjen vil utvikle seg – og vi ønsker å være i forkant. LIGL består av topp kvalifiserte forretningsadvokater med lang fartstid, solid faglig ekspertise og entusiasme for den jobben de gjør. Flere av firmaets advokater kommer fra ledende partnerstillinger i landets største advokatfirmaer. Kundene våre er norske og internasjonale virksomheter. Vi bistår alt fra gründervirksomheter i oppstart, til store selskaper med en lang historie å se tilbake på. Vi tar også oppdrag for privatpersoner innenfor utvalgte rettsområder. Firmaet leverer advokattjenester innen følgende fagområder: - Corporate, strategisk selskapsrettslig rådgivning - Rekonstruksjon & insolvens - Immaterialrett & teknologi - Fast eiendom - Skatt - Tvisteløsning Firmaets advokater er dyktige tverrfaglige forretningsadvokater, og firmaet tar derfor også oppdrag innenfor andre fagområder som naturlig leveres av et kompetent forretningsadvokatfirma, som arbeidsrett, kontraktsrett, entreprise etc.

Pridok AS er et Horten basert softwarefirma som har utviklet et nytt og moderne skybasert elektronisk pasientjournalsystem, Pridok EPJ på Microsoft Azure plattformen. Vi har tatt utgangspunkt i Helsedirektoratets kravspesifikasjon og lagt til ytterligere krav som vi har kartlagt.Pasientsikkerhet og kvalitetsikring av behandlingen er et stort fokusområde i Pridok EPJ. Nå kan legen for første gang bruke en EPJ-løsning uavhengig av plattform, enhet og som gir full mobilitet.Vi lar leger være leger uten at de må bruke tid på VPN, backup, servere etc.Flere hundre leger har forhåndsregistrert seg for løsningen vår som går i pilot våren 2017.

Vimond provides online streaming software and services for broadcasters and content providers worldwide. Our local team counts 62 people from 17 nations, of which a majority are developers with a strong passion and expertise in online video workflows and innovative software and web development. As we continue to grow our team, we are always looking for people with relevant experience in media technology, software development, product development, system administration & dev ops, tech team lead roles, project management, account management, and solution architect roles. Contact us for an informal chat!